Skip to content
    MDXG
    Earnings call· Jun 2026(Q2 FY26)

    MIMEDX GROUP Q2 FY26 earnings call MDXG

    Jul 29, 2026 Source

    Executive summary

    MiMedx Q2 FY26 — Sonera MedTech Acquisition and Wound Care Stabilization

    MiMedx announced the transformational acquisition of Sonera MedTech, significantly expanding its surgical franchise and projecting strong financial performance for the combined entity in 2027. Concurrently, the company reported sequential recovery in its wound care business despite ongoing Medicare reimbursement challenges, while maintaining a robust cash position and right-sizing its cost structure.

    Highlights

    5

    • Surgical revenue increased 15% year-over-year.

    • Company net sales grew 9% sequentially from Q1 to Q2.

    • Wound care center unit volume grew by double digits on both an annual and sequential basis.

    • Ended the quarter with $119 million in net cash.

    • Sonera MedTech acquisition expected to generate revenue well in excess of $400 million and adjusted EBITDA margin over 20% for the combined company in 2027.

    Concerns

    4

    • Net sales were $64 million, a 35% year-over-year decrease due to Medicare reimbursement changes.

    • Adjusted EBITDA loss of $8 million in Q2, including $5 million of additional bad debt expenses.

    • Gross margin declined to 69% from 81% in the prior year period.

    • Medicare reimbursement changes continue to impact the wound business, with MACs disorganized and the Wiser model described as a "complete disaster."

    Guidance & targets

    9
    CategoryTargetConfidence
    Combined Company Revenue
    well in excess of $400 million
    high materiality
    High
    Combined Company Adjusted EBITDA Margin
    over 20%
    high materiality
    High
    Combined Company Deleveraging Target
    under three times adjusted EBITDA
    medium materiality
    High
    Standalone Full-Year Net Sales
    $260 million and $290 million
    high materiality
    High
    Standalone Full-Year Adjusted EBITDA
    approaching breakeven
    high materiality
    High
    Gross Margin
    improve into the mid-70s range
    medium materiality
    High
    Sales and Marketing Expense as % of Net Sales
    between 62 and 64%
    medium materiality
    High
    R&D Expense
    approximately $3 to $3.5 million per quarter
    low materiality
    High
    Long-term Non-GAAP Effective Tax Rate
    approximately 25%
    low materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Surgical
    Growth was broad-based across the portfolio, including flagship placental sheet products and newly licensed products like Gel4Derm Plus.
    Domestic particulate subsegment growth: 21%
    		$39 million15%——
    Wound
    Business continues to be impacted by Medicare reimbursement changes, but shows early signs of stabilization with improving activity levels in wound care centers and hospital outpatient settings.
    Volume improvement: 22% sequentiallyWound care center unit volume growth: double digits (annual and sequential)Wound care center sequential volume growth: 44%
    		$25 milliondeclining 61%increased 11% sequentially—

    Operational metrics

    20
    Company Sequential Revenue Growth
    9%from Q1 to Q2
    Q2 FY26

    Sequential improvement in net sales.

    June Net Sales
    $24 million
    June 2026

    Highest net sales month for the calendar year.

    Adjusted Gross Profit Margin
    74%
    Q2 FY26

    Reported adjusted gross profit margin for the quarter.

    Adjusted EBITDA Loss
    $8 millioncompared to a $12 million loss in Q1
    Q2 FY26

    Includes $5 million of additional bad debt expenses.

    Additional Bad Debt Expenses
    $5 millionabove historic reserve levels
    Q2 FY26

    Primarily from private office accounts due to Medicare reimbursement changes; expected to be transitory.

    Historic Quarterly Bad Debt Run Rate
    $700,000
    quarterly

    Used for comparison to current bad debt expenses.

    Net Cash Balance
    $119 million
    Q2 FY26 end

    Cash balance at the end of the quarter.

    Share Repurchase Program
    $13 million
    Q2 FY26

    Amount deployed under the share repurchase plan before termination due to acquisition discussions.

    One-time Severance Costs
    $4 million
    Q2 FY26

    Related to cost reduction initiatives.

    Gross Margin
    69%compared to 81% last year
    Q2 FY26

    Decline primarily driven by lower wound pricing following Medicare reimbursement changes and unfavorable product mix.

    Sales and Marketing Expense
    $46 millioncompared to $48 million in prior year
    Q2 FY26

    Decrease driven by cost reduction initiatives, lower compensation, travel, meeting expenses, and lower commissions, largely offset by increased bad debt expense.

    General Administrative Expense
    $13 millioncompared to $16 million in prior year
    Q2 FY26

    Decrease primarily driven by lower compensation expense following cost reduction initiatives, partially offset by increased legal expenses.

    R&D Expense Reduction
    16%compared to prior year period
    Q2 FY26

    Reduction primarily driven by lower personnel costs following cost reduction initiatives.

    Effective Income Tax Rate
    17%compared to 26% in prior year period
    Q2 FY26

    Impacted by timing and deductibility of compensation-related expenses and restricted stock vestings.

    GAAP Net Loss
    $15 millioncompared to GAAP net income of $10 million in prior year
    Q2 FY26

    Reported GAAP net loss for the quarter.

    Adjusted Net Loss
    $7 millioncompared to adjusted net income of $15 million in prior year
    Q2 FY26

    Decline primarily reflects lower wound profitability, partially offset by restructuring and cost-reduction savings.

    Adjusted EBITDA
    negative $8 millioncompared to positive $24 million in prior year
    Q2 FY26

    Compared to 25% of net sales in the prior year period.

    Shares Repurchased
    close to three and a half million shares
    Q2 FY26

    Shares bought back before terminating the program for the Sonera acquisition.

    New Shares Issued for Sonera Acquisition
    just over 4 million new shares
    post-acquisition

    Expected shares to be issued as part of the Sonera MedTech acquisition.

    Net Increase to Float
    about 700,000 shares
    post-acquisition

    Net increase to the float since the buyback program, considering shares repurchased and new shares issued for Sonera.

    Industry KPIs

    1
    MetricValueDetails
    Regulatory approvals filingsFirst two 510K applications accepted for review

    Product announcements

    2
    ProductTypeDetails
    Gel4Derm Pluslaunch
    AmnioFix Thyroid Shieldslaunch

    Deals & partnerships

    3
    Sonera MedTechDefinitive agreement to acquire all outstanding shares of Sonera MedTech.$35 a share

    Sonera's revenue is greater than $100 million, 100% surgical, and its products are 510K cleared, unlocking $4 billion of new addressable market. Accelerate Rx accounted for approximately $80 million of LTM revenue. Sonera is roughly two-thirds musculoskeletal focused.

    Hafen Capital ManagementSecured committed financing for the Sonera acquisition with a term loan.$300 millionsix-year note

    The loan carries interest at SOFR plus 6.25% and is subject to various covenants. Hafen was a previous lender to the company.

    Citizens and Bank of AmericaInitiated prepayment of existing term loan.

    Prepayment of the existing term loan as the company moves towards closing the Sonera acquisition.

    Risks & headwinds

    6
    Medicare Reimbursement Changes Impact on Wound BusinessQ2 FY26, ongoing

    Net sales decreased 35% year-over-year; $5 million of additional bad debt expenses in Q2; significantly reduced reimbursement levels across the category.

    Mitigation: Right-sizing cost structure; aggressively pursuing collections; expecting bad debt expense to be transitory; expecting adjusted EBITDA to improve sequentially.

    MACs Disorganization in Processing ClaimsQ2 FY26, ongoing

    MACs are disorganized and behind in processing claims.

    Mitigation: Company is making progress despite this, focusing on market-leading technology and clinical evidence.

    Ineffective Implementation of Wiser ModelQ2 FY26, ongoing

    Wiser model is a "complete disaster"; prolonged prior authorization and ineffective implementation have been devastating for patients.

    Mitigation: Legislative directive for CMS to address the issue and report back to Congress; hope for relief.

    Competition from Low-Priced ProductsQ2 FY26, ongoing

    Extremely low-priced products are being dumped on the market.

    Mitigation: Focus on market-leading technology with unmatched clinical evidence; funding RCTs for new product introductions.

    Increased Audits and CallbacksQ2 FY26, ongoing

    Audits and callbacks are increasing.

    Mitigation: None explicitly stated, but company is working through overall market challenges.

    Proposed 2027 Physician Fee ScheduleFY27

    Indicates CMS has little interest in course correcting at this time; current system and reimbursement levels likely to remain in place throughout next year.

    Mitigation: Continuing to fund RCTs on two most recent product introductions; welcoming basic requirements for proof of product safety and efficacy.

    What to watch in Q3 FY26

    5

    Wound Care Sequential Volume Growth

    Q3 FY26
    Current22% (Q2 sequential volume growth); 44% (wound care center sequential volume growth)
    TargetContinued sequential growth

    Why it matters

    Indicates continued stabilization and recovery in the wound care business despite market headwinds🌐.

    For Q2, our wound care volume increased 22% compared to Q1. Within wound care centers, where we have been concentrating our efforts... we achieved 44% sequential volume growth.

    Q&A highlights

    7

    What makes the Sonera acquisition the right deal, specifically regarding Accelerate Rx, BioSurge, and Osteq, and their synergies/overlap with MiMedx's business?

    Joe Capper first highlighted MiMedx's strong standalone Q2 performance, including 15% surgical growth and significant sequential wound care volume growth. Regarding Sonera, he emphasized that the acquisition accelerates MiMedx's surgical expansion plan. He noted Accelerate Rx's market penetration, BioSurge's potential for expansion into wound care centers, and excitement for Osteq, a bone bioadhesive in development. He also stressed the critical importance of cultural alignment between the two teams.

    “Yes, this is a deal that makes a ton of sense for us. You've heard us talk about the importance of expanding our surgical portfolio on every one of these calls. ... This just accelerates that plan.”

    asked by Chase Knickerbocker · answered by Joseph Capper

    2 min read6 chapters

    Detailed Narrative

    01

    Sonera MedTech Acquisition Rationale

    MiMedx announced a definitive agreement to acquire Sonera MedTech for $35 per share, a move aimed at significantly expanding its surgical business. Sonera's portfolio, including Accelerate Rx and BioSurge, is highly complementary, profitable, and immediately accretive, opening up a new $4 billion addressable market. The transaction is anticipated to close by year-end 2026, with integration planning already underway.

    02

    Strategic Shift and Portfolio Mix

    The acquisition is expected to transform MiMedx's revenue composition, with approximately 75% of total revenue projected to come from surgical products and 25% from wound care. This aligns with the company's strategic focus on expanding its surgical footprint, creating a combined surgical business approaching $300 million in annual revenue across a broad range of subspecialties.

    03

    Wound Care Market Stabilization

    Despite ongoing challenges stemming from Medicare reimbursement changes, MiMedx reported early signs of stabilization in its wound care market. The company achieved a 22% sequential increase in wound care volume and a 44% sequential growth in wound care center volume in Q2. This progress indicates a positive trend amidst a difficult market, with patient migration to wound care centers contributing to the recovery.

    04

    Surgical Business Momentum

    The surgical segment demonstrated continued strong performance, achieving 15% year-over-year growth in Q2. This growth was broad-based across the portfolio, including flagship placental sheet products and newly licensed surgical products like Gel4Derm Plus. MiMedx is further augmenting its commercial team and product offerings to capitalize on this momentum.

    05

    Regulatory and Clinical Efforts

    MiMedx is actively pursuing regulatory clearances, having submitted its first two 510K applications, including one for a placental-derived particulate product, both of which were accepted for FDA review. The company also continues to invest in Randomized Controlled Trials (RCTs) for new product introductions, emphasizing clinical effectiveness as a key competitive differentiator in the market.

    06

    Cost Structure and Profitability

    The company has successfully implemented cost reduction initiatives, leading to an improvement in adjusted EBITDA loss from $12 million in Q1 to $8 million in Q2. Management expects to achieve near break-even by June and anticipates a return to profitability in the second half of the year, driven by these operational efficiencies and expected sequential revenue growth.

    AI-generated summary of the company’s earnings call. Not investment advice.